MK-0249 Terminated Phase 2 Trials for Hypopnoea Syndrome / Excessive Daytime Sleepiness / Obstructive Sleep Apnea (OSA) Treatment

IndicationsStatusPurposePhase
TerminatedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00620659Treatment of Refractory Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea/Hypopnea Syndrome (OSA/HS) Using Nasal Continuous Positive Airway Pressure (nCPAP) Therapy (0249-015)